<DOC>
	<DOCNO>NCT01046799</DOCNO>
	<brief_summary>The purpose study determine whether hepatitis B immunoglobin discontinue early hepatitis B virus ( HBV ) induce liver transplantation replace nucleoside analogue entecavir prevent hepatitis B reinfection .</brief_summary>
	<brief_title>Prevention Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>liver transplantation hepatitis B induce endstage liver disease absence coinfection HIV HCV female male patient &gt; = 18 year age evidence cause endstage liver disease patient fulfill criterion liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>shortterm HBIg</keyword>
	<keyword>lamivudine resistance</keyword>
</DOC>